Efficacy of Huaier granule combined with transcatheter arterial chemoembolization in treatment of primary liver cancer: a meta analysis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHANG Shaohua ¹ , TANG Ying ² , YUE Han ¹ , MAO Xingbo ¹ , HUANG Shenqiao ¹ ,  WU Guo ¹ , LI Jingdong ¹

1. The First Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;
2. Deparment of UItrasonic Diagnosis, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;

Corresponding?author：

WU Guo, Email: xnyywg@126.com

Keywords：

primary liver cancer; Huaier granules; transcatheter arterial chemoembolization; efficacy; safety

DOI：

10.7507/1007-9424.201910035

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically evaluate efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with Huaier granules in treatment of primary liver cancer (PLC).Methods The databases including the PubMed, Embase, Cochrane Library, Wanfang Data, CNKI, VIP were searched to obtain the relevant literatures of Huaier granule combined with TACE therapy (Huaier+TACE group) and alone TACE therapy (TACE group) in the treatment of PLC. The short-term curative effects (objective response rate and disease control rate), 6 and 12-month survival rates, immune function change, and adverse reactions were extracted. The RevMan 5.3 software was applied to carry out the meta analysis.Results Fifteen studies involving 1 781 cases were enrolled in this study, of which 876 cases underwent the Huaier+TACE, 905 underwent the TACE. The meta analysis results showed that the objective response rate and disease control rate, 6 and 12-month survival rates of the Huaier+TACE group were significantly more superior as compared with of the TACE group (P<0.05), the adverse reaction incidence had no significant difference (P>0.05). Compared with the TACE group, the CD4⁺/CD8⁺ of the Huaier+TACE group was significantly improved (P<0.05).Conclusion From results of meta analysis, Huaier granule combined with TACE could improve therapeutic effect, increase survival rate, and improve life quality of PLC.

Citation： ZHANG Shaohua, TANG Ying, YUE Han, MAO Xingbo, HUANG Shenqiao, WU Guo, LI Jingdong. Efficacy of Huaier granule combined with transcatheter arterial chemoembolization in treatment of primary liver cancer: a meta analysis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(7): 855-860. doi: 10.7507/1007-9424.201910035 Copy

1.	Pan R, Zhu M, Yu C, et al. Cancer incidence and mortality: A cohort study in China, 2008—2013. Int J Cancer, 2017, 141(7): 1315-1323.
2.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
3.	梁宏元, 盧再鳴. 原發性肝癌綜合介入治療現狀與困惑. 臨床肝膽病雜志, 2016, 32(1): 44-48.
4.	Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut, 2018, 67(11): 2006-2016.
5.	Long TT, Liu ZJ, Shang JC, et al. Polygonatum sibiricum polysaccharides play anti-cancer effect through TLR4-MAPK/NF-κB signaling pathways. Int J Biol Macromol, 2018, 111: 813-821.
6.	Li C, Wu X, Zhang HH, et al. A Huaier polysaccharide restrains hepatocellular carcinoma growth and metastasis by suppression angiogenesis. Int J Biol Macromol, 2015, 75: 115-120.
7.	Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
8.	郭添勝, 黃福喜, 曹小龍. 槐耳顆粒聯合介入治療原發性肝癌的療效觀察. 實用醫學雜志, 2005, 21(16): 1846-1847.
9.	洪政, 王洪濤. 槐耳顆粒聯合 TACE 治療原發性肝癌臨床觀察. 中華實用中西醫雜志, 2006, 19(23): 2841-2843.
10.	闕勁松, 高世洪. 槐耳顆粒聯合介入療法治療原發性肝癌的療效觀察. 臨床和實驗醫學雜志, 2007, 6(5): 151.
11.	陳文林, 吳海江, 馬傳學, 等. 介入治療加槐耳顆粒治療原發性肝癌的臨床觀察. 江蘇省藥學會·第八屆江蘇省藥師周論文集, 2008: 163-164.
12.	王天昌, 蔣明, 崔菲. 槐耳顆粒聯合介入治療原發性肝癌的療效觀察. 中國實用醫刊, 2009, 36(14): 79-80.
13.	李馨剛, 許炎. 槐耳顆粒口服聯合介入療法治療原發性肝癌的細胞免疫變化. 中國民康醫學, 2009, 21(18): 2196, 2230.
14.	杜更全, 董志強. 槐耳顆粒聯合 TACE 治療中晚期肝癌的療效觀察. 中國醫藥指南, 2012, 10(21): 446-447.
15.	汪平, 仲煒, 唐成武, 等. 槐耳顆粒對肝癌栓塞化療后免疫功能的影響. 中國現代醫生, 2013, 51(36): 58-60.
16.	孫學征, 趙振華, 黃志坤, 等. 槐耳顆粒聯合 TACE 對中晚期肝癌患者T淋巴細胞亞群的影響. 中國中醫藥科技, 2013, 20(1): 66.
17.	趙廣生, 劉影, 張躍偉, 等. 明膠海綿微粒與洛鉑經肝動脈化療栓塞聯合槐耳顆粒治療原發性肝癌. 中華普通外科雜志, 2013, 28(6): 440-443.
18.	吳暉. 槐耳顆粒聯合化療栓塞術治療原發性肝癌 96 例. 中國藥業, 2014, 23(3): 16-18.
19.	華向東, 尚海, 何忠野, 等. 槐耳顆粒聯合經導管肝動脈化療栓塞在原發性肝癌伴微血管侵犯根治術后的療效分析. 中國普外基礎與臨床雜志, 2016, 23(8): 982-986.
20.	蔣蕊. 槐耳顆粒對肝癌栓塞化療后患者的影響探討. 臨床醫藥文獻電子雜志, 2017, 4(63): 12423, 12425.
21.	董德碩, 劉兆玉. 基于真實世界肝動脈化療栓塞術聯合槐耳顆粒治療肝細胞癌的臨床研究. 現代腫瘤醫學, 2018, 26(5): 741-746.
22.	王冠蕾, 富大智, 王本剛. 槐耳顆粒聯合吡柔比星介入治療乙型肝炎肝癌患者的臨床療效. 世界中醫藥, 2018, 13(7): 1597-1600.
23.	Nie J, Zhao C, Deng LI, et al. Efficacy of traditional Chinese medicine in treating cancer. Biomed Rep, 2016, 4(1): 3-14.
24.	Li C, Wu X, Zhang H, et al. A Huaier polysaccharide inhibits hepatocellular carcinoma growth and metastasis. Tumour Biol, 2015, 36(3): 1739-1745.

1. Pan R, Zhu M, Yu C, et al. Cancer incidence and mortality: A cohort study in China, 2008—2013. Int J Cancer, 2017, 141(7): 1315-1323.
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
3. 梁宏元, 盧再鳴. 原發性肝癌綜合介入治療現狀與困惑. 臨床肝膽病雜志, 2016, 32(1): 44-48.
4. Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut, 2018, 67(11): 2006-2016.
5. Long TT, Liu ZJ, Shang JC, et al. Polygonatum sibiricum polysaccharides play anti-cancer effect through TLR4-MAPK/NF-κB signaling pathways. Int J Biol Macromol, 2018, 111: 813-821.
6. Li C, Wu X, Zhang HH, et al. A Huaier polysaccharide restrains hepatocellular carcinoma growth and metastasis by suppression angiogenesis. Int J Biol Macromol, 2015, 75: 115-120.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
8. 郭添勝, 黃福喜, 曹小龍. 槐耳顆粒聯合介入治療原發性肝癌的療效觀察. 實用醫學雜志, 2005, 21(16): 1846-1847.
9. 洪政, 王洪濤. 槐耳顆粒聯合 TACE 治療原發性肝癌臨床觀察. 中華實用中西醫雜志, 2006, 19(23): 2841-2843.
10. 闕勁松, 高世洪. 槐耳顆粒聯合介入療法治療原發性肝癌的療效觀察. 臨床和實驗醫學雜志, 2007, 6(5): 151.
11. 陳文林, 吳海江, 馬傳學, 等. 介入治療加槐耳顆粒治療原發性肝癌的臨床觀察. 江蘇省藥學會·第八屆江蘇省藥師周論文集, 2008: 163-164.
12. 王天昌, 蔣明, 崔菲. 槐耳顆粒聯合介入治療原發性肝癌的療效觀察. 中國實用醫刊, 2009, 36(14): 79-80.
13. 李馨剛, 許炎. 槐耳顆粒口服聯合介入療法治療原發性肝癌的細胞免疫變化. 中國民康醫學, 2009, 21(18): 2196, 2230.
14. 杜更全, 董志強. 槐耳顆粒聯合 TACE 治療中晚期肝癌的療效觀察. 中國醫藥指南, 2012, 10(21): 446-447.
15. 汪平, 仲煒, 唐成武, 等. 槐耳顆粒對肝癌栓塞化療后免疫功能的影響. 中國現代醫生, 2013, 51(36): 58-60.
16. 孫學征, 趙振華, 黃志坤, 等. 槐耳顆粒聯合 TACE 對中晚期肝癌患者T淋巴細胞亞群的影響. 中國中醫藥科技, 2013, 20(1): 66.
17. 趙廣生, 劉影, 張躍偉, 等. 明膠海綿微粒與洛鉑經肝動脈化療栓塞聯合槐耳顆粒治療原發性肝癌. 中華普通外科雜志, 2013, 28(6): 440-443.
18. 吳暉. 槐耳顆粒聯合化療栓塞術治療原發性肝癌 96 例. 中國藥業, 2014, 23(3): 16-18.
19. 華向東, 尚海, 何忠野, 等. 槐耳顆粒聯合經導管肝動脈化療栓塞在原發性肝癌伴微血管侵犯根治術后的療效分析. 中國普外基礎與臨床雜志, 2016, 23(8): 982-986.
20. 蔣蕊. 槐耳顆粒對肝癌栓塞化療后患者的影響探討. 臨床醫藥文獻電子雜志, 2017, 4(63): 12423, 12425.
21. 董德碩, 劉兆玉. 基于真實世界肝動脈化療栓塞術聯合槐耳顆粒治療肝細胞癌的臨床研究. 現代腫瘤醫學, 2018, 26(5): 741-746.
22. 王冠蕾, 富大智, 王本剛. 槐耳顆粒聯合吡柔比星介入治療乙型肝炎肝癌患者的臨床療效. 世界中醫藥, 2018, 13(7): 1597-1600.
23. Nie J, Zhao C, Deng LI, et al. Efficacy of traditional Chinese medicine in treating cancer. Biomed Rep, 2016, 4(1): 3-14.
24. Li C, Wu X, Zhang H, et al. A Huaier polysaccharide inhibits hepatocellular carcinoma growth and metastasis. Tumour Biol, 2015, 36(3): 1739-1745.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Efficacy of Huaier granule combined with transcatheter arterial chemoembolization in treatment of primary liver cancer: a meta analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content